Drug intelligence / Profile preview

VinSan

Development stage: Preclinical
Lead developer: Kensana Health
Modality: Small Molecules
Administration: Topical

Overview

VinSan is a preclinical-stage phytopharmaceutical candidate developed by Kensana Health for the treatment of first-degree burns. It is a cannabinoid-based topical therapy designed to interact with the endocannabinoid system (ECS) to provide supportive care for minor burns. The drug aims to leverage the anti-inflammatory and analgesic properties of cannabinoids to promote healing and symptom relief. As a phytopharmaceutical, it is derived from plant sources and formulated for topical application directly to the site of the burn.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on VinSan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VinSan.

Explore the full profile